IL31RA (interleukin-31 receptor alpha) functions as a heterodimeric receptor component that associates with OSMR to form the functional IL-31 receptor, which activates STAT3 and to a lesser extent STAT1 and STAT5 1. The receptor is broadly expressed on dorsal root ganglia neurons, keratinocytes, and innate immune cells 1. IL31RA mediates IL-31-induced itch through direct stimulation of sensory neurons expressing TRPV1 and TRPA1 cation channels 2, establishing a critical neuroimmune link between TH2 cells and sensory nerves 2. This IL-31/IL31RA axis is central to pruritus in atopic disorders, particularly atopic dermatitis and prurigo nodularis 13. IL31RA signaling also contributes to immune regulation through positive effects on myeloid progenitor cell survival and differentiation. Clinically, IL31RA antagonism via nemolizumab significantly reduces itch and improves skin lesions in prurigo nodularis, with 56.3% of patients achieving itch response at week 16 compared to 20.9% with placebo 4. Similarly, nemolizumab effectively reduces pruritus in atopic dermatitis patients 5. The receptor also functions in broader neuroimmune communication relevant to neuroinflammatory diseases beyond dermatology 1.